Lorenzo Aguzzoli

Dr. Lorenzo Aguzzoli

orcid

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 March 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
Andrea GianniniAndrea Giannini
Andrea Giannini
VDViolante Di Donato
Violante Di Donato
FSFrancesco Sopracordevole
Francesco Sopracordevole
ACAndrea Ciavattini
Andrea Ciavattini
AGAlessandro Ghelardi
Alessandro Ghelardi
GBGiorgio Bogani
Giorgio Bogani
The objective of this work is to assess the 5-year outcomes of patients undergoing conization for high-grade cervical lesions that simultaneously present as risk factors in the persistence of HPV infection and the positivity of surgical resection margins. This is a retrospective study evaluating patients undergoing conization for high-grade cervical lesions. All patients included had both positive surgical margins and experienced HPV persistence at 6 months. Associations were evaluated with Cox proportional hazard regression and summarized using hazard ratio (HR). The charts of 2966 patients undergoing conization were reviewed. Among the whole population, 163 (5.5%) patients met the inclusion criteria, being at high risk due to the presence of positive surgical margins and experiencing HPV persistence. Of 163 patients included, 17 (10.4%) patients developed a CIN2+ recurrence during the 5-year follow-up. Via univariate analyses, diagnosis of CIN3 instead of CIN2 (HR: 4.88 (95%CI: 1.10, 12.41); p = 0.035) and positive endocervical instead of ectocervical margins (HR: 6.44 (95%CI: 2.80, 9.65); p < 0.001) were associated with increased risk of persistence/recurrence. Via multivariate analyses, only positive endocervical instead of ectocervical margins (HR: 4.56 (95%CI: 1.23, 7.95); p = 0.021) were associated with worse outcomes. In this high-risk group, positive endocervical margins is the main risk factor predicting 5-year recurrence.

19 July 2015 in Diagnostic Pathology
Verified
Journal Article
Open access
PDF file
VMVincenzo Dario Mandato
Vincenzo Dario Mandato
SSSusanna Santagni
Susanna Santagni
ACAlberto Cavazza
Alberto Cavazza
LALorenzo Aguzzoli
Lorenzo Aguzzoli
MAMartino Abrate
Martino Abrate
GSGiovanni Battista La Sala
Giovanni Battista La Sala
Cellular Angiofibroma (CA) represents a quite recently described mesenchymal tumour that occurs in both genders, in particular in the vulvo-vaginal region in women and in the inguino-scrotal area in men. The first description of this tumour dates from Nucci et al. article in 1997; since then, the literature reports different reviews and case report of this tumour in both genders, but no article specifically addressing CA treatment and follow-up in women. In this review we collected all 79 published female CA cases, analyzing the clinical, pathological and immunohistochemical features of the tumour. CA affects women mostly during the fifth decade of life, it is generally a small and asymptomatic mass that mainly arises in the vulvo-vaginal region, although there are reported pelvic and extra-pelvic cases. The treatment requires a simple local excision due to an extremely low ability to recurrent locally and no chance to metastasize. Throughout the immunohistochemical and pathological findings it is also easily possible a differential diagnosis from the other soft tissue tumours which affect the vulvo-vaginal area, such as spindle cell lipoma, solitary fibrous tumour, angiomyofibroblastoma and aggressive angiomyxoma.

1 August 2005 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
Fabio ParazziniFabio Parazzini
Fabio Parazzini
CBCarlo Bertulessi
Carlo Bertulessi
APAndrea Pasini
Andrea Pasini
MRMaurizio Rosati
Maurizio Rosati
FSFabio Di Stefano
Fabio Di Stefano
PBPaolo Beretta
Paolo Beretta

1 July 1995 in Placenta
Verified
Journal Article
Closed access
FPFelice Petraglia
Felice Petraglia
LALorenzo Aguzzoli
Lorenzo Aguzzoli
AGA. Gallinelli
A. Gallinelli
PFP. Florio
P. Florio
MZM. Zonca
M. Zonca
KWK. Woodruff
K. Woodruff

1 December 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
GBGiorgio Bogani
Giorgio Bogani
FRFrancesco Raspagliesi
Francesco Raspagliesi
FSFrancesco Sopracordevole
Francesco Sopracordevole
ACAndrea Ciavattini
Andrea Ciavattini
AGAlessandro Ghelardi
Alessandro Ghelardi
VDViolante Di Donato
Violante Di Donato
Background: Primary prevention through vaccination is a prophylactic approach aiming to reduce the risk of developing human papillomavirus (HPV)-related lesions. No mature and long-term data supported the adoption of vaccination in women undergoing conization. Methods: This is a retrospective multi-institutional study. Charts of consecutive patients undergoing conization between 2010 and 2014 were collected. All patients included had at least 5 years of follow-up. We compared outcomes of patients undergoing conization plus vaccination and conization alone. A propensity-score matching algorithm was applied in order to reduce allocation biases. The risk of developing recurrence was estimated using Kaplan-Meir and Cox hazard models. Results: Overall, charts of 1914 women were analyzed. The study group included 116 (6.1%) and 1798 (93.9%) women undergoing conization plus vaccination and conization alone, respectively. Five-year recurrence rate was 1.7% (n = 2) and 5.7% (n = 102) after conization plus vaccination and conization alone, respectively (p = 0.068). After the application of a propensity-score matching, we selected 100 patients undergoing conization plus vaccination and 200 patients undergoing conization alone. The crude number of recurrences was 2 (2%) and 11 (5.5%) for patients undergoing conization plus vaccination and conization alone, respectively (p = 0.231). Vaccination had no impact on persistent lesions (no negative examination between conization and new cervical dysplasia; p = 0.603), but reduced the risk of recurrent disease (patients who had at least one negative examination between conization and the diagnosis of recurrent cervical dysplasia; p = 0.031). Conclusions: Patients having vaccination experience a slightly lower risk of recurrence than women who had not, although not statistically significantly different. Further evidence is needed to assess the cost effectiveness of adopting vaccination in this setting.

9 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
GBGiorgio Bogani
Giorgio Bogani
LLLuca Lalli
Luca Lalli
FSFrancesco Sopracordevole
Francesco Sopracordevole
ACAndrea Ciavattini
Andrea Ciavattini
AGAlessandro Ghelardi
Alessandro Ghelardi
VDViolante Di Donato
Violante Di Donato
Background: Cervical dysplasia persistence/recurrence has a great impact on women’s health and quality of life. In this study, we investigated whether a prognostic nomogram may improve risk assessment after primary conization. Methods: This is a retrospective multi-institutional study based on charts of consecutive patients undergoing conization between 1 January 2010 and 31 December 2014. A nomogram assessing the importance of different variables was built. A cohort of patients treated between 1 January 2015 and 30 June 2016 was used to validate the nomogram. Results: A total of 2966 patients undergoing primary conization were analyzed. The median (range) patient age was 40 (18–89) years. At 5-year of follow-up, 6% of patients (175/2966) had developed a persistent/recurrent cervical dysplasia. Median (range) recurrence-free survival was 18 (5–52) months. Diagnosis of CIN3, presence of HR-HPV types, positive endocervical margins, HPV persistence, and the omission of HPV vaccination after conization increased significantly and independently of the risk of developing cervical dysplasia persistence/recurrence. A nomogram weighting the impact of all variables was built with a C-Index of 0.809. A dataset of 549 patients was used to validate the nomogram, with a C-index of 0.809. Conclusions: The present nomogram represents a useful tool for counseling women about their risk of persistence/recurrence after primary conization. HPV vaccination after conization is associated with a reduced risk of CIN2+.